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Jakub Tolar,1 Parinda A. Mehta,2 Mark C. Walters3Hereditary disorders that trace their origin to the hematopoietic stem cell have been targeted for allogeneic
therapy and were among the first human diseases cured by successful hematopoietic cell transplantation
(HCT). More recently, the possibility of treating nonhematopoietic hereditary disorders in which engraft-
ment of hematopoietic cells might ameliorate tissue damage in target organs has also been investigated
with encouraging results. As in the malignant hematological disorders, transplantation results have improved
over the past 3 decades as a consequence of more refined donor selection and patient risk stratification with
modifications to the conditioning regimen. The application of these principles is described in this update
about HCT for hereditary marrow failure syndromes and hemoglobin disorders. In addition, a novel indica-
tion of HCT for epidermolysis bullosa is presented. Together, these representative disorders illustrate the
potential for an expanding role of HCT for nonmalignant disorders.
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Blood and Marrow TransplantationHEMATOGENOUS CELLS FOR
EXTRACELLULAR MATRIX DEFICIENCY
EPIDERMOLYSIS BULLOSA
One of the most fascinating and daunting chal-
lenges of current transplantation biology is to harness
the potential of stem cells for tissue regeneration.
Adoptive transfer of hematopoietic stem cells can, of
course, regenerate the lymphohematopoietic system
in the recipients of hematopoietic cell transplantation
(HCT), but only recently have we and others obtained
evidence that bone marrow and cord blood transplan-
tation can mediate tissue repair in the largest extrame-
dullary organ—the skin.
The skin is constantly exposed to environmental in-
sults and requires effective repair tools to maintain its
protective function. Skin repair is a highly organized1Blood and Marrow Transplantation, University of
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6/j.bbmt.2011.10.023process that integrates the skin cells, skin extracellular
matrix, and systemic factors—mainly blood cells and
cytokines—into dynamic tissue healing. Keratinocytes
and dermal fibroblasts express adhesive proteins that
ensure the epidermis remains attached to the skin base-
ment membrane and to the papillary dermis. Congen-
ital deficiency of any of at least 15 such proteins results
in a blistering condition called epidermolysis bullosa
(EB) [1]. Of the multiple forms of EB, the severest are:
 recessive dystrophic EB (RDEB) caused by mutations
in the collagen type VII (C7) gene (COL7A1), and
 junctional EB (JEB) caused by loss-of-function
mutations in one of the three genes (LAMA3,
LAMB3, andLAMC2) that encodeoneof three chains
in the heterotrimeric protein laminin 332 (L332).
C7 and L332 deficiencies result in severe scarring,
contractures, and, ultimately, shortened survival—
most often because of infections and aggressive squa-
mous cell carcinoma. Even though suffering is difficult
to measure objectively, the painful challenges that
individuals with EB endure are extraordinary. EB skin
can blister with a touch, and the resulting wounds heal
with mutilating scarring. Their upper alimentary tract
can blister just as easily. Esophageal strictures develop
with aberrant tissue repair, and eating is painful. People
withEBare separated frommany interactionswith their
peers, as most common daily activities are impossible
for them. Everymoment and aspect of their lives is con-
sumed by this debilitating genodermatosis [2].
Remarkably, stem cell transplantation can amelio-
rate the deficiency of this skin-specific structural
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that donor cells at the dermal-epidermal junction pro-
duced C7 in the skin of the RDEB mice. Strikingly,
paw blisters healed and rudimentary homotrimers of
C7, termed anchoring fibrils, were formed [4]. These
data were supported by the research of others, who
demonstrated the positive effect of in utero infusion
of bone marrow cells in RDEB and postnatal infusions
in JEB [5,6].
Based on these proof-of-concept studies in murine
models that show the replacement of missing C7 and
skin repair, a first in-human study was initiated in
2007. After this clinical trial of allogeneic HCT in
seven children with RDEB had shown that C7 can in-
crease and ameliorate many of the disease manifesta-
tions [7], we hypothesized that children with JEB
could respond favorably to allogeneic transplantation
as well, and that both groups could benefit from coin-
fusion of hematopoietic and mesenchymal stem cells
(MSCs) from allogeneic marrow.
To investigate this, we treated eight additional
children with RDEB and two children with JEB using
allogeneic cotransplantation of hematopoietic and
MSCs. Altogether, 17 patients have been treated,
with survival in 13 and clinical amelioration of the dis-
ease in 11. Healthy donor cells from the hematopoietic
graft migrated to the injured skin. Simultaneously,
there has been an increase in the production of C7
and L332 and increased skin integrity with reduced
tendency to blister formation. The results of these tri-
als demonstrate that the infusion of allogeneic hemato-
poietic cells can result in substantial clinical benefit [8].
Laboratory investigations in EB show that:
1. Unique among proteins critical to skin integrity,
C7 function depends on extracellular polymeriza-
tion. This makes RDEB the ideal human skin
condition to explore, and thus illuminate, the
mechanisms of cross-correction of structural pro-
tein deficiency in extracellular matrix.
2. Depletion of cells with high proliferative potential
from skin stem cell niches by hyperactive unpro-
ductive tissue repair in EBmay facilitate high donor
cell engraftment. The empty stem cell niches in EB
skin that are depleted of their own stem cells by
repeated and futile attempts at skin regeneration,
may serve as permissive ‘‘docking stations’’ for
donor cells. Such cells may, in turn, release factors
that operate on the host or that may differentiate
into cells that directly participate in the wound-
healing process via release of C7, L332, or other tis-
sue repair proteins. Simultaneously, this further
supports the idea of EB as a unique model of skin
tissue repair with donor regenerative cells [9].
3. The novel technology of reprogramming skin cells
into pluripotent stem cells (iPSCs) by a combination
of specific transcription factors can further illumi-nate the early stages of aberrant skin formation in
development and, in principle, provide an inex-
haustible supply of EB patient-specific stem cells
that can be useful for future stem cell gene therapy
strategies [10].
Clinical trials in EB illustrate that:
1. Translation of laboratory observations in relevant
animalmodels to a clinicallymeaningful intervention
is possible within a short period of time (\2 years).
2. Further modifications in the use of stem cell trans-
plantation as a durable source of extracellular ma-
trix proteins may make this regenerative medicine
approach effective in other cutaneous and extra-
cutaneous conditions.
3. Only by performing the laboratory and clinical ex-
perimentation that contributed to achievement of
the original objectives do we learn about the nature
of ‘‘the growing frontier.’’ Thus, only in the context
of new data do previously unanticipated questions
emerge, both biologic, for example, how robust
must hematogenous engraftment be to significantly
contribute to skin repair?; and ethical, for example,
how much preliminary data are enough to substan-
tiate clinical trials in infants with severe phenotype
versus adults with a mild form of the same disease?
In summary, significant biochemical and quality-
of-life benefits can be derived from allogeneic hemato-
poietic and mesenchymal cell transplantation for
RDEB and JEB, conditions characterized by severely
compromised wound healing because of the congenital
absence of skin structural proteins. These severe
congenital mechanobullous disorders are unique in
their capacity to illuminate the mechanisms of cross-
correction of a structural protein deficiency in extracel-
lular matrix and regeneration of extramedullary tissues
by hematogenous cells in disease and injury states.HCT FOR CHROMOSOME SENSITIVITY
SYNDROMES
DNA is continuously damaged by endogenous and
exogenous (eg, ionizing radiation) mutagens. Repair of
DNA damage (DNA double- and single-strand breaks)
is a complex process carried out by an array of DNA
repair pathways (eg, homologous recombination, non-
homologous end-joining). Defects in any of these
repair mechanisms or in telomere maintenance can
lead to chromosome instability syndromes. The chro-
mosome instability syndromes mainly manifest as con-
genital bone marrow failure (BMF) syndromes (eg,
Fanconi anemia, Shwachman-Diamond syndrome
[SDS], dyskeratosis congenita [DC], Bloom syndrome,
and Nijmegen breakage syndrome and a variety of pri-
mary immune deficiency disorders such as severe
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IV, Artemis, Cernunnos, etc.).
Congenital BMF syndromes are associated with
a range of congenital anomalies, impaired hematopoie-
sis leading to progressive marrow failure, and cancer
predisposition. The typical clinical features of these dis-
orders are generally well known to practicing hematolo-
gists, although they are sometimes overlooked in adult
practice where they present less frequently. However,
it is becoming increasingly apparent that patients lack-
ing characteristic physical stigmata may still harbor
a congenital BMF syndrome. In addition, some patients
present with clinical symptoms for the first time as an
adult. Sensitive and specific diagnostic tests, including
identification of mutations in specific genes, are now
available formany of these disorders. This is particularly
useful while evaluating patients with suspected marrow
failure syndrome, and it is essential for screening sibling
donors, to ensure that an affected sibling is not used as
a stem cell donor. HCT remains the only potentially
curative option for many of these disorders. However,
the inherent chemotherapy and radiation sensitivity
makes transplantation for these disorders challenging.FANCONI ANEMIA
Fanconi anemia (FA) is a genetic disorder character-
ized by congenital anomalies, progressive BMF, and
predisposition tomalignancies. The cellular phenotype
of FA is characterized by an abnormally high level of
baseline chromosomal breakage along with an in-
creased sensitivity to DNA cross-linking or alkylating
agents [11]. The earliest attempts at transplanting pa-
tients with FA (1970s and 1980s) used 50 mg/kg of cy-
clophosphamide  4 days. These transplantations had
high mortality and morbidity. This study provided the
first clinical evidence of a special sensitivity of FA cells
to alkylating chemotherapy agents. Such hypersensitiv-
ity was also observed in vitro when FA cells were
incubated with alkylating agents. Gluckman and col-
leagues [12] were the first to investigate a markedly at-
tenuated conditioning regimen for patients with FA
and successfully demonstrated that HCT could be
safely performed using low-dose cyclophosphamide,
with long-term survival in 75% of patients. They also
confirmed the suspected increased radiosensitivity in
the majority of patients with FA. Following these re-
sults, patients were conditioned with low-dose cyclo-
phosphamide (20 mg/kg) in combination with 5 Gy
thoracoabdominal irradiation. The addition of antithy-
mocyte globulin (ATG) to the Gluckman regimen was
the next important milestone. Themost recent of these
reports showed a 10-year actuarial survival rate of 89%,
with a significant decrease in acute (23%) and chronic
(12%) graft-versus-host disease (aGVHD and
cGVHD) in amatched sibling donorHCTsetting [13].Over the last 3 decades, these regimens have been
modified significantly, with the goal of limiting toxicity
while maintaining engraftment and improving
outcomes by decreasing GVHD. An additional impor-
tant goal is to minimize the development of secondary
malignancies in these patients. Kapelushnik and
colleagues [14] were the first to report use of
a fludarabine-based conditioning regimen for a child
withFA in leukemic transformation.This highly immu-
nosuppressive nucleoside analog is well tolerated by
patients with FA, as it does not cause direct DNA
damage and has allowed for the elimination of radiation
in a matched sibling donor setting with good results.
Outcomes of unrelated donor (URD)HCT for FA
have been inferior, primarily because of high risk of
graft failure, aGVHD, and excessive regimen-related
organ toxicity. Before the introduction of fludarabine
in theFA-preparative regimen, survival forURD trans-
plants was approximately 30%. Three groups in the
United States including Cincinnati Children’s Hospi-
tal, University of Minnesota, and Memorial Sloan-
Kettering Cancer Center have pioneered regimens
that include low-dose total-body irradiation (TBI),
cyclophosphamide, ATG, and fludarabine followed
by T cell-depleted marrow or peripheral blood stem
cell transplants [15-17]. All three centers have had
promising results. However, with the small number
of patients with FA who undergo allogeneic HCT,
results of single-center trials are difficult to interpret
in terms of optimal cytoreductive regimens and dosing.
Reported survival rates with fludarabine-containing
preparative regimens range from 38% to 96%. In an
attempt to decrease late secondary malignancies and
improve immune recovery in this vulnerable popula-
tion, the Minnesota group has shown that the TBI
dose can be reduced to 300 cGY. However, further re-
duction led to graft failure.
Most recently with a similar goal, a multi-
institutional study is ongoing at four centers, using
a chemotherapy- only preparative regimen, containing
pharmacokinetically adjusted low-dose busulfan,
cyclophosphamide, fludarabine, and rabbit ATG. All
grafts are T cell depleted using the CliniMacs CD34
columns (Miltenyi, Auburn, CA). So far, engraftment,
early toxicity, and infection data appear to be similar to
historical TBI-based protocols, with no graft failures
after 15 of a planned 25 transplants. Overall, these
results appear promising, and future patients will likely
not need radiation.SDS
HCT is the only known curative treatment for bone
marrow failure associated with SDS. Similar to FA, chil-
dren with SDS tend to have increased toxicity with
intensive conditioning regimens. Various case reports/
series describe fatal congestive heart failure, neurologic
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gan failure with typical ablative regimens containing
cyclophosphamide. In one review, more than 50% of
the patients succumbed to cardiopulmonary complica-
tions in the early posttransplantation phase. Similarly,
a review of the European experience with HCT in 26
SDS patients [18], reported an overall treatment-
related mortality of 35.5% at 1 year. Interestingly, they
found a significantly highermortality rate in patients re-
ceiving a TBI-containing conditioning regimen (67%
for TBI versus 20% for non-TBI-containing regimen;
P 5 .03). Recent efforts have thus focused on reduced-
intensity conditioning (RIC) regimens to ameliorate car-
diac and pulmonary toxicities. Sauer and colleagues [19]
usedfludarabine, treosulfan, andmelphalan, andwehave
previously reportedour experiencewith successful useof
anRICregimenconsistingofCampath-1H,fludarabine,
andmelphalan. These data indicate thatHCTwith RIC
is feasible in patients with SDS and is associated with ex-
cellent donor cell engraftment and modest morbidity.DC
DC is an inherited disorder that usually presents
with the clinical triad of abnormal skin pigmentation,
nail dystrophy, and mucosal leukoplakia. Noncutane-
ous manifestations include progressive liver cirrhosis
and pulmonary fibrosis. The availability of a simple
diagnostic blood test measuring telomere length and
genetic testing that is positive in about 50% of patients
has greatly increased recognition of this disorder. Out-
comes of allogeneic HCT have been poor because of
early and late complications. Langstone and colleagues
[20] performed transplantation on eight patients with
DC and BMF. Six who underwent transplantation us-
ing matched sibling donors were conditioned with cy-
clophosphamide (140-200 mg/kg) with or without
ATG, and two with matched URD received cyclo-
phosphamide (120 mg/kg) and TBI (1200 cGy). Three
patients died from respiratory failure and pulmonary
fibrosis at 70 days, 8 years, and 20 years posttransplan-
tation. Three patients died early from invasive fungal
infections, one died from refractory aGVHD on day
44, and one patient was alive at 463 days, who under-
went surgical resection of a rectal carcinoma 14
months post HCT. Other reports using myeloablative
conditioning showed similar results.
The presence of pulmonary disease in a significant
proportion of DC patients before HCT may explain
the high incidence of fatal pulmonary complications
in the HCT setting. More recent studies have used
RIC with encouraging results for successful engraft-
ment with fewer complications, for both related and
unrelated allografts [25]. Tolar et al. recently pub-
lished their experience with a RIC regimen contain-
ing cyclophosphamide, fludarabine, alemtuzumab,
and a single 200 cGy dose of TBI. Four patientswere alive with full donor engraftment at a median
follow-up of 26.5 months [21]. At our center, we
have adopted RIC with Campath 1H, fludarabine,
and melphalan, with the melphalan dose reduced by
50% to avoid excessive regimen-related toxicity and
mortality. One of these patients with DC and myelo-
dysplastic syndrome with monosomy 7 is 1 year post-
transplantation, with normal hematopoiesis and no
evidence of monosomy 7. Of note, this, patient did
not receive Campath to avoid risk of mixed chime-
rism and potential relapse of myelodysplastic syn-
drome. However, long-term follow-up data are not
available, and it remains to be seen how these patients
ultimately fare. Regardless of the potential reduction
in toxicity associated with these regimens, preexisting
characteristics of DC (eg, pulmonary and liver dis-
ease) may ultimately limit the effectiveness of HCT
in these patients.
In summary, progress in improving the outcomes
for children with chromosomal sensitivity syndromes
has been limited by the rarity of these disorders, as
well as disease-specific genetic, molecular, cellular,
and clinical characteristics that increase the risks of
complications associated with HCT. However, recent
progress has been made, as best evidenced by use of
various RIC regimens with improved outcomes and
by improved diagnostic testing. The rarity of these
diseases, coupled with the likely incremental im-
provements that will result from ongoing research
will require prospective multicenter or even interna-
tional clinical trials to improve the outcome for these
children.HCT FOR HEMOGLOBINOPATHIES
The hemoglobinopathies, which account for the
most common hereditary disorders worldwide, are
curable by HCT. But unlike rarer hereditary disor-
ders of childhood that often are rapidly fatal in the
absence of HCT, expanded and improved supportive
therapies for hemoglobin disorders now routinely ex-
tend the life span of affected individuals well into
adulthood [22,23]. As a consequence, in regions of
the world where this healthcare is readily available,
HCT is pursued infrequently in children with these
disorders because of a perception among families
and their physicians that the risk-benefit balance has
shifted away from HCT [24]. More recently, how-
ever, there has emerged a growing consensus that
survival into adulthood is accompanied by chronic
and life-threatening complications, and this new un-
derstanding has caused many to reconsider the role
of HCT for these disorders, particularly in young
adult patients in whom the quality of life has declined
[25]. Thus, transplantation investigators are now
challenged by how to make HCT successful in older
individuals where risks of GVHD, graft rejection, and
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ative impact on outcomes. In this brief review, we will
examine what has and has not been successful in elu-
cidating a successful approach to HCT for hemoglo-
binopathies and speculate about the best future
prospects for expanding the role of HCT.
The curative potential of HCT for hemoglobin-
opathies was proved first in thalassemia major and
later in sickle cell disease, utilizing a myeloablative
backbone of busulfan and cyclophosphamide before
HLA-identical (ID) sibling bone marrow transplanta-
tion (reviewed in [26]). These initial studies showed
a very high success rate, with failures caused either
by transplant-related deaths or more frequently, graft
rejection accompanied by autologous reconstitution
and disease recurrence. The risk of disease recurrence
in thalassemia was highest in pediatric recipients who
had poor-risk features such as hepatomegaly, hepatic
fibrosis, or poor adherence to regular iron chelation
therapy before HCT. In addition, transplant-related
mortality in young adults with thalassemia ranged
from 27% to 37% [27]. Together, these clinical series
showed that it was possible to treat hemoglobinopa-
thies successfully by HCT and that patient selection
affected outcome. However, as most affected individ-
uals lacked an HLA-ID sibling donor, the application
of HCT for hemoglobinopathies was not broadly
expanded, and for the most part was restricted to
children.
Several recent patient series show progress in how
to tackle the problems of graft rejection and condi-
tioning regimen toxicity, and in so doing, should
help expand HCT beyond the realm of HLA-ID sib-
ling bone marrow transplantation. First, by extending
the duration and intensity of pretransplantation im-
munosuppression by administering azathioprine and
hydroxyurea 6 weeks before HCT and by adding flu-
darabine to the conditioning regimen, it was possible
to improve transplantation outcomes in high-risk pe-
diatric thalassemia recipients [28]. Similarly, the re-
placement of fludarabine for cyclophosphamide in
the conditioning regimen resulted in an acceptable
toxicity profile and was sufficient for engraftment af-
ter unrelated donor bone marrow transplantation in
children and young adults [29]. The use of treosulfan
in lieu of busulfan also appeared to generate excellent
results in the unrelated donor setting [30]. Thus, it
appears that modulation of the conditioning regimen
in such a manner that might amplify suppression of
the host-versus-graft rejection has served to make en-
graftment of donor cells more likely to occur, even
after alternate-donor HCT. Similarly, the use of al-
ternative and novel chemotherapeutic agents in the
conditioning regimen might also improve the toxicity
profile.
Other obvious strategies to extend transplantation
more safely and broadly have also been pursued, withmixed results. There are now several series that report
only transient donor engraftment after nonmyeloabla-
tive preparation following a minimal toxicity regimen,
and this strategy has been dropped for the most
part [31]. There has been better success with engraft-
ment after applying reduced-intensity regimens that
accomplish immunoablation by incorporating the use
of alemtuzumab. One recent trial in adults with sickle
cell diseasewho also received sirolimus for postgrafting
immunosuppression experienced stable donor-host
chimerism when postgrafting immunosuppression
was extended long term after HCT [32]. Several multi-
center clinical trials are being conducted to explore the
utility of a combination of alemtuzumab with melpha-
lan and fludarabine in children with hemoglobinopa-
thies based upon promising preliminary experience
with this regimen in children with nonmalignant con-
ditions. The use of umbilical cord blood (UCB) as
a source of donor cells has also been tested, as this
source of hematopoietic cells extends a lower risk of
GVHD, a complication that carries no benefit in non-
malignant conditions. Initial reports showed that UCB
fromHLA-ID sibling donors, either alone or in combi-
nation with marrow from the same sibling donor,
showed results that were very similar to outcomes after
bone marrow transplantation, with a reduced risk of
GVHD [33]. Attempts to extend these results by using
unrelatedUCBdonors have been disappointing, due in
large part to a high rate of graft rejection, particularly
after nonmyeloablative preparation [34]. Thus, the fu-
ture use of UCB from unrelated donors for this indica-
tion is uncertain today.
In summary, the investigations and clinical expe-
rience reported to date indicate that there is an un-
usually difficult barrier to allogeneic engraftment
after HCT for hemoglobinopathies, which remains
incompletely understood. Nonetheless, there is very
good empirical evidence that aggressive inhibition
of the host immune system is required for engraft-
ment, using either myeloablative or immunoablative
therapy for pretransplant conditioning. This is partic-
ularly important in the setting of unrelated and HLA-
mismatched donor HCT. It is also very likely that
donor availability will continue to create challenges,
especially in light of the poor results after unrelated
UCB transplantation that have diminished enthusi-
asm for this source of hematopoietic cells. Thus, it
is possible that renewed effort will be focused on
the use of HLA-mismatched and haploidentical re-
lated donors. Of course, this approach also carries
a significant challenge of how to overcome the barrier
to engraftment, as was highlighted in a recent thalas-
semia trial [35]. But improved methodologies, such as
the use of postgrafting high-dose cyclophosphamide,
might provide a novel path to engraftment without
significant GVHD [36]. Additional investigations
into the causes of graft rejection and clinical trials
Biol Blood Marrow Transplant 18:S166-S171, 2012 S171HCT for Nonmalignant Disordersof novel transplantation designs that mitigate this risk
will be needed to advance alternative donor trans-
plantation for hemoglobinopathies.ACKNOWLEDGMENTS
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